Related Experiment Video

Updated: May 26, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Re: A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment

Patrick C Walsh

    The Journal of Urology
    |December 14, 2011
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
    06:32

    Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

    Published on: November 4, 2022

    Related Experiment Videos

    Last Updated: May 26, 2026

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
    06:32

    Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

    Published on: November 4, 2022

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation.

    The Prostate·2026

    Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes.

    The Prostate·2025

    Germline Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes Recommended by NCCN Guidelines.

    The Prostate·2025

    Discovery of a Recurrent Frameshift Ashkenazi Jewish Founder Mutation (F722fs) in the PARP Inhibitor-sensitive MMS22L Gene Associated with Higher Risk of Prostate Cancer.

    European urology focus·2025

    Association of rare, recurrent nonsynonymous variants in the germline of prostate cancer patients of African ancestry.

    The Prostate·2022

    A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry.

    European urology·2022

    Bladder Cancer Incidence in Patients with Microhematuria at the Veterans Health Administration.

    The Journal of urology·2026

    Age- and sex-specific prevalence of lower urinary tract symptoms and bowel dysfunction in children: Results from a National Survey.

    The Journal of urology·2026

    Onvansertib-mediated PLK1 inhibition impairs spermatogenesis in the murine testis.

    Asian journal of andrology·2026

    RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR-T Resistant Large B-cell Lymphomas.

    Blood cancer discovery·2026

    BUB1B Mitotic Kinase Dependency Reveals CENP-E Inhibition as a Tractable Approach for Castration and Enzalutamide Resistant Prostate Cancer.

    Cancer research·2026

    Emerging therapeutic strategies and clinical development of investigational agents for conventional chondrosarcoma.

    Expert opinion on investigational drugs·2026

    MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis.

    Future oncology (London, England)·2026

    Real-world treatment patterns in men with metastatic hormone-sensitive prostate cancer in Europe and Asia between 2020 and 2024.

    The oncologist·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us